fenproporex

01/01/2016 - "To evaluate clinical evidence on the safety and efficacy of fenproporex for treating obesity. "
01/01/2016 - "Safety and efficacy of fenproporex for obesity treatment: a systematic review."
01/01/2016 - "Eligible studies were all those placebo-controlled that provided data on the efficacy and safety of Fenproporex to treat obesity. "
05/01/1970 - "[Study of the lipolytic action of fenproporex in obesity by measuring skinfold thickness]."
03/01/1968 - "[Clinical experimentation with fenproporex in the treatment of obesity. "

01/01/2016 - "These studies suggest that Fenproporex is modestly effective in promoting weight loss. "
01/01/2016 - "Fenproporex produced additional weight reductions of 4.7 kg (one year), 3.8 kg (six months) and 1.55 kg (two months) in average, in relation to diet and exercise only (three trials). "
01/01/2016 - "All controlled studies found that weight loss among Fenproporex-treated patients was greater than that produced by the placebo, but drug effect was modest. "
01/01/2012 - "Of the 106 weight loss products sampled, four (3.8%) were found to be adulterated by fenproporex or sibutramine. "
04/01/2002 - "Our results showed that the CSF/serum leptin ratio decreased after weight loss in obese women treated during 2 months with orlistat, whereas this ratio did not change in this period of time in obese women treated with fenproporex and sibutramine."

05/01/2017 - "The aim of this study was to evaluate efficacy and safety of amfepramone, fenproporex and mazindol as a monotherapy for the treatment of obese or overweight patients. "
01/01/2019 - "PubMed, EMBASE, and Cochrane library databases were searched from inception until January 2018 to retrieve randomized controlled trials comparing sibutramine, diethylpropion, mazindol, and fenproporex versus placebo in overweight or obese patients. "
11/01/2013 - "Despite the street illegal drugs such as amphetamine and ecstasy, some amphetamine-like compounds are also legally marketed under medical prescription in the treatment of attention deficit-hyperactivity disorder (methylphenidate) and obesity/overweight (fenproporex and diethylpropione). "

04/01/2014 - "Fenproporex increases locomotor activity and alters energy metabolism, and mood stabilizers reverse these changes: a proposal for a new animal model of mania."
01/01/2017 - "Omega-3 Fatty Acids and Mood Stabilizers Alter Behavioural and Energy Metabolism Parameters in Animals Subjected to an Animal Model of Mania Induced by Fenproporex."
04/01/2014 - "Fenproporex (Fen) is converted in vivo into amphetamine, which is used to induce mania-like behaviors in animals. "
01/01/2017 - "Therefore, the study aimed to evaluate the effect of ω3 fatty acids alone and in combination with lithium (Li) or valproate (VPA) on behaviour and parameters of energy metabolism in an animal model of mania induced by fenproporex. "
03/01/2014 - "Considering these evidences, the present study aimed to investigate the effects of ω3 fatty acids on locomotor behavior and oxidative stress parameters (TBARS and protein carbonyl content) in brain of rats subjected to an animal model of mania induced by fenproporex. "

06/10/2013 - "The chemical analysis revealed that the seizures capsules labeled as Desobesi-M (fenproporex 25mg), actually contained the active pharmaceutical ingrediente (API) sibutramine. "
11/01/2014 - "The CE method demonstrated sufficient selectivity to discriminate the two target drugs, MDMA and mCPP, from the other drugs present in seizures, namely amphepramone, fenproporex, caffeine, lidocaine, and cocaine. "